Form D · Biotechnology
TB Biosciences, Inc.
Bethlehem, PA · CIK 0001578956
Offering snapshot reported Jun 12, 2013 · SEC filing
- Reported sold
- $1.25M Offering amount: $1.5M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 31, 2013 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 12, 2013 | Initial | $1,250,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-197829
Source: Form D, filed Jun 12, 2013. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Michael Gausling | Director |
| R. Sam Niedbala | Director, Executive |
| David Oxely | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
205 Webster Street
Bethlehem, PA, 18015
Bethlehem, PA, 18015